ArticleTherapeutic advances in gastroenterology2023
Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of
Article in Therapeutic advances in gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Insights intoFrontiers in microbiology · 2024Pooled it
- A Quality Improvement Initiative to Increase Helicobacter pylori Testing and Eradication Among Patients Diagnosed With Peptic Ulcer Disease in a U.S. Safety-Net Hospital.Journal of clinical gastroenterology · 2026Article
- Crystal structure of carbon-nitrogen hydrolase from Helicobacter pylori G27.Acta crystallographica. Section F, Structural biology communications · 2026Article
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- Antimicrobial Resistance Patterns and Determinants ofAntibiotics (Basel, Switzerland) · 2025Article
- [Establishment and optimization of a routinely resistance testing of Helicobacter pylori to encourage a resistance-guided therapy].Zeitschrift fur Gastroenterologie · 2025Article
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.Minerva gastroenterology · 2025Review
- Co-crystal structure of Helicobacter pylori biotin protein ligase with biotinyl-5-ATP.Acta crystallographica. Section F, Structural biology communications · 2025Article
- Evolving Concepts in Helicobacter pylori Management.Gastroenterology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective: To evaluate the efficacy of clarithromycin-based triple eradication regimens over time. Design: A comprehensive literature review and time-trend analysis. Data sources and methods: Bibliographies of recently published systematic literature reviews were searched and supplemented with a targeted literature review conducted using Medline and Embase databases and ProQuest from conception to May 2021. Studies reporting Results: Eradication rates for triple therapies containing proton pump inhibitors (PPIs), clarithromycin, and amoxicillin showed a significant decline over the past 23 years ( Conclusion: Vonoprazan-based triple therapy partially mitigated the decline in eradication rates seen with PPI-based triple therapy, likely due to more powerful acid suppression of vonoprazan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.